RT Journal Article
SR Electronic
T1 A modified SEIR meta-population transmission based Modeling and Forecasting of the COVID-19 pandemic in Pakistan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20121517
DO 10.1101/2020.06.03.20121517
A1 Hassan, Sohaib
A1 Mughal, Bilal Javed
A1 Siwiak, Marian
A1 Yasin, Zafar
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121517.abstract
AB The coronavirus disease 2019 (COVID-19) started from China at the end of 2019, has now spread across the globe. Modeling and simulation of the COVID-19 outspread is significant for timely and effective measures to be taken. Scientists around the world are using various epidemiological models to help policymakers to plan and determine what interventions and resources will be needed in case of a surge and to estimate the potential future burden on health care system. Pakistan is also among the affected countries with 18th highest number of total detected number of cases, as of 3rd of June, 2020. A modified time-dependent Susceptible-Exposed-Infected-Recovered (SEIR) metapopulation transmission model is used in the Global Epidemic and Mobility Model (GLEaM) for this simulation. The simulation assumes the index case in Wuhan, China and models the global spread of SARS-COV-2 with reasonable results for several countries within the 95% confidence interval. This model was then tuned with parameters for Pakistan to predict the outspread of COVID-19 in Pakistan. The impact of Non-Drug Interventions on “flattening the curve” are also incorporated in the simulation and the results are further extended to find the peak of the pandemic and future predictions. It has been observed that in the current scenario, the epidemic trend of COVID-19 spread in Pakistan would attain a peak in the second decade of month of June with approximately (3600-4200) daily cases. The current wave of SARS-COV-2 in Pakistan with is estimated to cause some (210,000 – 226,000) cumulative cases and (4400-4750) cumulative lost lives by the end of August when the epidemic is reduced by 99%. However, the disease is controllable in the likely future if inclusive and strict control measures are taken.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available online